These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28464520)

  • 1. Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m
    Blute ML; Kucherov V; Rushmer TJ; Damodaran S; Shi F; Abel EJ; Jarrard DF; Richards KA; Messing EM; Downs TM
    BJU Int; 2017 Sep; 120(3):387-393. PubMed ID: 28464520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence.
    Rausch S; Hennenlotter J; Todenhöfer T; Aufderklamm S; Schwentner C; Sievert KD; Stenzl A; Gakis G
    Urol Oncol; 2014 Nov; 32(8):1178-83. PubMed ID: 24962661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
    Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
    Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL
    Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer.
    Li CE; Chien CS; Chuang YC; Chang YI; Tang HP; Kang CH
    Int Urol Nephrol; 2016 Jun; 48(6):993-9. PubMed ID: 26995008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative chronic kidney disease predicts poor prognosis in patients with primary non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e1-684.e8. PubMed ID: 32201059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Kobatake K; Hayashi T; Black PC; Goto K; Sentani K; Kaneko M; Yasui W; Mita K; Teishima J; Matsubara A
    Int J Urol; 2017 Aug; 24(8):594-600. PubMed ID: 28734027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of recurrence in non-muscle invasive bladder cancer patients. Do patient characteristics matter?
    Ucpinar B; Erbin A; Ayranci A; Caglar U; Alis D; Basal S; Sarilar O; Akbulut MF
    J BUON; 2019; 24(4):1659-1665. PubMed ID: 31646822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Suppression Therapy Is Associated with Lower Recurrence of Non-muscle-invasive Bladder Cancer.
    Wu SC; Kwon D; Jue JS; Chen FV; Velasquez Escobar MC; Punnen S; Parekh DJ; Ritch CR; Gonzalgo ML
    Eur Urol Focus; 2021 Jan; 7(1):142-147. PubMed ID: 31103602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
    Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
    Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
    Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
    BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes.
    Tseng CL; Lafrance JP; Lu SE; Soroka O; Miller DR; Maney M; Pogach LM
    BMC Nephrol; 2015 Mar; 16():34. PubMed ID: 25885708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumour in non-muscle-invasive bladder cancer.
    Jancke G; Rosell J; Jahnson S
    Scand J Urol; 2014 Jun; 48(3):276-83. PubMed ID: 24286506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.
    von Landenberg N; Aziz A; von Rundstedt FC; Dobruch J; Kluth LA; Necchi A; Noon A; Rink M; Hendricksen K; Decaestecker KPJ; Seiler R; Poyet C; Fajkovic H; Shariat SF; Xylinas E; Roghmann F;
    Urol Oncol; 2018 May; 36(5):238.e19-238.e27. PubMed ID: 29506940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results.
    Naito S; Algaba F; Babjuk M; Bryan RT; Sun YH; Valiquette L; de la Rosette J;
    Eur Urol; 2016 Sep; 70(3):506-15. PubMed ID: 27117749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
    Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
    BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of glomerular filtration rate: does haemoglobin discriminate between ageing and true CKD?
    Ferrari P; Xiao J; Ukich A; Irish A
    Nephrol Dial Transplant; 2009 Jun; 24(6):1828-33. PubMed ID: 19131346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification.
    Kohada Y; Hayashi T; Hsi RS; Yukihiro K; Sentani K; Goto K; Inoue S; Ohara S; Teishima J; Kajiwara M; Nishisaka T; Yasui W; Black PC; Matsubara A
    BJU Int; 2021 Apr; 127(4):473-485. PubMed ID: 32805763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
    Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
    PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease.
    Perkins RM; Kirchner HL; Hartle JE; Bucaloiu ID
    Clin Nephrol; 2013 Oct; 80(4):256-62. PubMed ID: 23993165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.